Patients
Tumors, allergy, Cancer
METASTATIC TUMOR, BRAIN METASTASES, ALLERGY, METASTATIC DISEASE, TUMORS, SYSTEMIC INFECTION, CONGESTIVE HEART FAILURE, HEART, CANCER
Between July 2017 and July 2021, female patients with histologically confirmed HER2-negative MBC previously treated with conventional anthracyclines and taxanes were enrolled in this study. HER2 negativity was defined as a 0 or 1 + on immunohistochemistry and/or negativity by fluorescence in situ hybridization in a primary or metastatic tumor sample. Other eligibility criteria included age ≥ 18 and ≤ 70 years; at least one but no more than four lines of prior systemic chemotherapy for metastatic disease; at least one measurable lesion according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1[Exclusion criteria were as follows: congestive heart failure (New York Heart Association class II or higher); untreated or uncontrolled brain metastases; severe systemic infection; allergy to PLD or other related supplementary materials; prior anthracycline exceeding a total cumulative dose of 300 mg/mThis study was approved by the Ethics Committee of Peking University Cancer Hospital (Approval ID: 2017YJZ08) in Beijing, China, and was registered in the Chinese Clinical Trial Registry (ChiCTR1900022568). This study was conducted according to the Declaration of Helsinki and Good Clinical Practice Guidelines. All participants provided written informed consent.